Last updated on August 2020

Multi-center Single Arm Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diabetes Mellitus | Diabetes Mellitus Type 2 | Diabetes Mellitus Types I and II | NIDDM | Type 2 | Diabetes (Pediatric) | Diabetes Prevention
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Provision of subject informed consent prior to any study specific procedures.
  • Chinese, Female or male.
  • T2DM diagnosed by physicians according to 2013 Chinese Guideline for Diabetes, ie. 1) Patients with typical syndrome and with a FPG 7.0mmol/L and/or random plasma glucose 11.1mmol/L; and/or, 2) patients without typical syndrome and with repeated FPG 7.0mmol/L and/or 2 hour post challenged plasma glucose 11.1mmol/L.
  • Subjects who already took at least one dose of dapagliflozin, which is prescribed by physicians based on their clinical practice. The prescription of dapagliflozin is separated from the decision to be included in the current study or not.

Exclusion Criteria:

  • Being unable to comply with study-specified procedures.
  • Participating in any other clinical trial currently or during the last 3 months.
  • Previous enrolment in the present study.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.